国际医药卫生导报2015，Vol.21Issue(7)：911-913,3.DOI:10.3760/cma.j.issn.1007-1245.2015.07.008
胸腺肽对于复治涂阳肺结核患者的治疗价值分析
Thymosin in treatment of retreatment smear-positive pulmonary tuberculosis
陈新灿1
作者信息
- 1. 251700 滨州市中心医院结防院结核三科
- 折叠
摘要
Abstract
Objective To explore the therapeutic value ofthymosin in the treatment ofretreatment smear-positive pulmonary tuberculosis.Methods 160 patients with retreatment smear-positive pulmonary tuberculosis admitted into our hospital from January 1st,2012 to June 30th,2014 were voluntarily and randomly divided into a treatment group and a control group.The control group was given conventional chemotherapy.In addition,the treatment group was treated with thymosin.Both groups were continuously treated for 4 weeks.The sputum bacteria detection results,clinical symptoms and adverse drug reactions of the two groups were compared and analyzed.Results The sputum negative rate of the treatment group was 93.4％,which was significantly higher than that of the control group (76.3％);the time for sputum becoming negative of the treatment group was (6.87±2.13) d,which was significantly lower than that of the control group [(10.76±2.87)d](P＜0.05);the total effective rate of the treatment group was 90.0％,which was significantly higher than that of the control group (67.5％) (P＜0.05).Conclusions The therapeutic value of thymosin combined with anti-tuberculosis drug for retreatment smear-positive pulmonary tuberculosis and is an effective option with acceptable side effects is worth being clinically generalized.关键词
胸腺肽/复治涂阳肺结核/临床治疗Key words
Thymosin/Retreatment smear-positive pulmonary tuberculosis/Clinical efficacy引用本文复制引用
陈新灿..胸腺肽对于复治涂阳肺结核患者的治疗价值分析[J].国际医药卫生导报,2015,21(7):911-913,3.
